EA200300155A1 - Терапевтическая комбинация ингибитора сетр и аторвастатина - Google Patents

Терапевтическая комбинация ингибитора сетр и аторвастатина

Info

Publication number
EA200300155A1
EA200300155A1 EA200300155A EA200300155A EA200300155A1 EA 200300155 A1 EA200300155 A1 EA 200300155A1 EA 200300155 A EA200300155 A EA 200300155A EA 200300155 A EA200300155 A EA 200300155A EA 200300155 A1 EA200300155 A1 EA 200300155A1
Authority
EA
Eurasian Patent Office
Prior art keywords
atorvastatin
inhibitor
cetr
therapeutic combination
combinations
Prior art date
Application number
EA200300155A
Other languages
English (en)
Inventor
Чарльз Лестер Шир
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200300155A1 publication Critical patent/EA200300155A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Фармацевтические комбинации ингибитора СЕТР и аторвастатина, или его гидроксиметаболитов, или его фармацевтически приемлемой соли, способы применения такой комбинации и наборы, содержащие такие комбинации для лечения атеросклероза, стенокардии, повышенного уровня холестерина и для помощи больным с риском сердечных заболеваний.Отчет о международном поиске был опубликован 2003.03.13.
EA200300155A 2000-08-15 2001-07-23 Терапевтическая комбинация ингибитора сетр и аторвастатина EA200300155A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22523800P 2000-08-15 2000-08-15
PCT/IB2001/001309 WO2002013797A2 (en) 2000-08-15 2001-07-23 Therapeutic combination of a cetp inhibitor and atorvastatin

Publications (1)

Publication Number Publication Date
EA200300155A1 true EA200300155A1 (ru) 2003-08-28

Family

ID=22844100

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300155A EA200300155A1 (ru) 2000-08-15 2001-07-23 Терапевтическая комбинация ингибитора сетр и аторвастатина

Country Status (27)

Country Link
US (1) US20020035125A1 (ru)
EP (1) EP1309329A2 (ru)
JP (1) JP2004506008A (ru)
KR (1) KR20030069983A (ru)
CN (1) CN1735416A (ru)
AP (1) AP2003002743A0 (ru)
AU (1) AU2001270937A1 (ru)
BG (1) BG107515A (ru)
BR (1) BR0113200A (ru)
CA (1) CA2419406A1 (ru)
CZ (1) CZ2003390A3 (ru)
DZ (1) DZ3409A1 (ru)
EA (1) EA200300155A1 (ru)
EC (1) ECSP034478A (ru)
HR (1) HRP20030104A2 (ru)
HU (1) HUP0303083A3 (ru)
IL (1) IL154348A0 (ru)
IS (1) IS6700A (ru)
MX (1) MXPA03001419A (ru)
NO (1) NO20030725D0 (ru)
PA (1) PA8525301A1 (ru)
PE (1) PE20020340A1 (ru)
SK (1) SK1742003A3 (ru)
SV (1) SV2003000600A (ru)
TN (1) TNSN01125A1 (ru)
UY (1) UY26883A1 (ru)
WO (1) WO2002013797A2 (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044459A1 (en) * 2001-09-04 2003-03-06 Pfizer Inc. Biomodulated multiparticulate formulations
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
EP1581210B1 (en) 2002-12-20 2008-03-19 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ES2310676T3 (es) * 2002-12-20 2009-01-16 Pfizer Products Inc. Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de hmg-coa reductasa.
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CN1812983A (zh) * 2003-05-30 2006-08-02 兰贝克赛实验室有限公司 取代的吡咯衍生物及其作为hmg－co抑制剂的用途
CA2534371A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
SG146695A1 (en) 2003-09-26 2008-10-30 Japan Tobacco Inc Method of inhibiting remnant lipoprotein production
EP1737811B1 (en) * 2004-04-13 2016-08-10 Merck Sharp & Dohme Corp. Cetp inhibitors
EP1845953A1 (en) * 2005-02-03 2007-10-24 Pfizer Products Incorporated Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
CA3089847C (en) 2009-02-10 2024-04-09 Amarin Pharmaceuticals Ireland Limited Use of eicosapentaenoic acid to treat hypertriglyceridemia
PL2424356T3 (pl) 2009-04-29 2018-03-30 Amarin Pharmaceuticals Ireland Limited Stabilna farmaceutyczna kompozycja i sposoby jej stosowania
CN106822080A (zh) 2009-04-29 2017-06-13 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (ja) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
MX2020008890A (es) 2012-06-29 2022-08-15 Amarin Pharmaceuticals Ie Ltd Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
AU2157400A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method

Also Published As

Publication number Publication date
UY26883A1 (es) 2002-03-22
TNSN01125A1 (fr) 2005-11-10
EP1309329A2 (en) 2003-05-14
AU2001270937A1 (en) 2002-02-25
BG107515A (en) 2003-09-30
DZ3409A1 (fr) 2002-02-21
WO2002013797A3 (en) 2003-03-13
CN1735416A (zh) 2006-02-15
CZ2003390A3 (en) 2004-03-17
SV2003000600A (es) 2003-01-13
WO2002013797A2 (en) 2002-02-21
MXPA03001419A (es) 2003-06-06
HUP0303083A3 (en) 2005-05-30
IS6700A (is) 2003-01-27
CA2419406A1 (en) 2002-02-21
HRP20030104A2 (en) 2003-04-30
SK1742003A3 (en) 2004-06-08
NO20030725D0 (no) 2003-02-14
KR20030069983A (ko) 2003-08-27
ECSP034478A (es) 2003-03-31
JP2004506008A (ja) 2004-02-26
PE20020340A1 (es) 2002-05-10
PA8525301A1 (es) 2002-04-25
HUP0303083A2 (hu) 2003-12-29
IL154348A0 (en) 2003-09-17
US20020035125A1 (en) 2002-03-21
AP2003002743A0 (en) 2003-03-31
BR0113200A (pt) 2003-09-16

Similar Documents

Publication Publication Date Title
EA200300155A1 (ru) Терапевтическая комбинация ингибитора сетр и аторвастатина
BG104075A (en) Combined treatment including atorvastatin and an antihypertonic form
TR200000561T2 (tr) Amlodipin ve atorvastatin içeren tedavisel bileşikler.
HUP0003103A2 (hu) Az amlodipin és egy sztatin vegyület felhasználása kombinált terápiában
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
GT199900015A (es) Procedimiento para tratar la insuficiencia cardiaca
DE69814394D1 (de) Verwendung von levobupivacain
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
NO20013158D0 (no) Preparater av kolesterylesteroverföringsproteininhibitorer og fibrinsyrederivater for kardiovaskul¶re indikasjoner
ITTO20000441A0 (it) Composizione terapeutica per la cura della psoriasi.
PT1183046E (pt) Derivado de aminotetralina para a terapia de doencas cardiovasculares
ATE316374T1 (de) Antikonvulsive derivate zur behandlung von essentiellem tremor
ATE261965T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
AP1708A (en) Method for preventing or delaying catheter-based revascularization.
NO20014889D0 (no) Fremgangsmåte for fremstilling av medisinske midler
ATE259809T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
RU2001112719A (ru) Способ лечения стенокардии и алекситимии у больных пожилого возраста
RU2001123675A (ru) Средство бальзам "ГРААЛЬ" для лечения сердечно-сосудистой системы и заболеваний крови человека
ECSP982646A (es) Combinaciones terapeuticas
ECSP993240A (es) Preparaciones de combinacion farmaceutica